Delta-Fly Pharma, Inc. (TYO:4598)

Japan flag Japan · Delayed Price · Currency is JPY
145.00
-2.00 (-1.36%)
Jun 4, 2026, 3:30 PM JST
Market Cap1.76B -61.6%
Revenue (ttm)n/a
Net Income-1.63B
EPS-140.37
Shares Out 12.16M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume164,300
Open145.00
Previous Close147.00
Day's Range144.00 - 147.00
52-Week Range142.00 - 793.00
Beta-0.76
Analystsn/a
Price Targetn/a
Earnings DateMay 15, 2026

About Delta-Fly Pharma

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 13
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4598
Full Company Profile

Financial Performance

Financial Statements